CANAVERAL
Live / Applied — First extension granted (statement of use) (as of 11 Mar 2026)
What this means for you
Not registered yet, but its 17 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99005505
- Mark type
- Stylized text
- Filed
- 17 Jan 2025
- Published for opposition
- 02 Dec 2025
- Attorney of record
- Kristin H. Altoff
Goods and services
- Class 005 — Pharmaceuticals: Biological preparations, namely, nucleic acids, proteins, and peptides for medical and veterinary purposes; Chemical and biological diagnostic preparations and substances, namely, nucleic acids, proteins and polypeptides, small molecules for medical or veterinary purposes in clinical and medical laboratory use in drug discovery and nucleic acid and protein therapeutics in the bio-pharmaceutical industry; Nucleic acid-protein conjugates for medical or veterinary purposes; Nucleic acids for medical purposes; Nucleic acid therapeutic pharmaceuticals for the treatment of extra-hepatic disease; nucleic acid and protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases; Pharmaceutical preparations, namely, nucleic acid and protein therapeutics for the treatment of a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases; Pharmaceuticals using protein biotherapeutics to treat a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases; Pharmaceutical preparations containing nucleic acid and protein therapeutics for the treatment of immune system, infectious disease, pulmonary diseases and disorders, genetic diseases, metabolic diseases, kidney diseases, reproductive disorders, gastrointestinal diseases, cancers, and obesity; Protein therapeutic pharmaceuticals for the treatment of human conditions, namely a variety of diseases, namely, autoimmune and inflammatory diseases, metabolic diseases, cancer, chronic kidney diseases, rare diseases, genetic diseases, respiratory diseases, and infectious diseases.
- Class 042 — Scientific and technological services: Biotechnology, medical and scientific research, and development services in the field of nucleic acid and protein therapeutics and diagnostics; Biotechnology research services, namely, nucleic acid and protein therapeutics development for applications in the lung, pediatric, gastrointestinal, reproductive, kidney, metabolic, infectious disease, cancer, immunological, and genetic disciplines; Medical and scientific research and development services in the field of nucleic acid and protein therapeutics and diagnostics; Research and development of medicines; Pharmaceutical research and development services in the field of nucleic acid and protein therapeutics.
Owner
- Canaveral Medicines, Inc., Boston, MA, US
- Canaveral Medicines, Inc., Boston, MA, US
Prosecution history
- 11 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Mar 2026 — SOU EXTENSION 1 GRANTED
- 11 Mar 2026 — SOU EXTENSION 1 FILED
- 11 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 27 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Dec 2025 — PUBLISHED FOR OPPOSITION
- 26 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 31 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 31 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 09 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 09 Aug 2025 — NON-FINAL ACTION E-MAILED
- 09 Aug 2025 — NON-FINAL ACTION WRITTEN